Clinical efficacy of peloidotherapy on pain, sleep quality, and central sensitization-related symptoms in chronic low back pain: a comparative analysis
International Journal of Biometeorology · 2026
DOI: 10.1007/s00484-026-03225-1 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Biometeorology, 2026. Verfasst von Nihal Yılmaz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, Usak University Faculty of Medicine, Atatürk Avenue, 1.Eylül Campus, UŞAK, 6400, Turkey. Hauptthemen laut MEDLINE: Low Back Pain, Sleep Quality, Chronic Pain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Usak University.
Themen: Schlaf
Abstract (Originalsprache)
This study aimed to investigate the effect of peloidotherapy applied in chronic low back pain on pain and central sensitization and its reflections on patients’ sleep quality, fatigue levels, functional capacity, and disability status. In this prospective, randomized, single-blind study, 74 patients were assigned to the Electrotherapy Group (EG: hot pack+TENS+exercise) or Peloidotherapy Group (PG: peloidotherapy+TENS+exercise) for 15 sessions. Treatments were administered 5 days per week for 3 weeks. Clinical assessments were performed pre/post-treatment using the Visual Analog Scale (VAS), Central Sensitization Inventory (CSI), Quebec Back Pain Disability Scale (QBPDS), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), Pittsburgh Sleep Quality Index (PSQI), and EQ-5D-3 L. Both groups showed significant within-group improvements in most outcomes (all p < 0.001), except for the EQ-5D index in the EG. According to the ANCOVA results adjusted for baseline values and pain duration, the PG demonstrated significantly superior post-treatment outcomes compared to the EG in VAS ( p = 0.006), EQ-5D index ( p = 0.004), and PSQI ( p = 0.044) scores. Furthermore, the adjusted delta score analysis confirmed that the improvements in the PG were significantly greater than those in the EG for VAS ( p = 0.026), EQ-5D ( p = 0.004), and PSQI ( p = 0.044). In contrast, no significant between-group differences were observed for CSI, QBPDS, FACIT, or EQ-5D VAS scores ( p > 0.05). Both treatments improved pain and central sensitization-related measures, likely due to shared thermal effects. While peloidotherapy showed superior improvements in pain intensity, sleep quality, and health status, no specific superior effect on CSI scores was demonstrated compared to electrotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physical Medicine and Rehabilitation, Usak University Faculty of Medicine, Atatürk Avenue, 1.Eylül Campus, UŞAK, 6400, Turkey.
- Department of Physical Medicine and Rehabilitation, Usak University Faculty of Medicine, Atatürk Avenue, 1.Eylül Campus, UŞAK, 6400, Turkey. kagan.ozkuk@usak.edu.tr.
- Department of Medical Ecology and Hydroclimatology, Usak University Faculty of Medicine, Usak, Turkey. kagan.ozkuk@usak.edu.tr.
Förderung
- Usak University
Zitieren
APA
Yılmaz, N., & Özkuk, K. (2026). Clinical efficacy of peloidotherapy on pain, sleep quality, and central sensitization-related symptoms in chronic low back pain: a comparative analysis. International Journal of Biometeorology. https://doi.org/10.1007/s00484-026-03225-1
Vancouver
Yılmaz N, Özkuk K. Clinical efficacy of peloidotherapy on pain, sleep quality, and central sensitization-related symptoms in chronic low back pain: a comparative analysis. International Journal of Biometeorology. 2026. doi:10.1007/s00484-026-03225-1
BibTeX
@article{Ylmaz2026,
author = {Yılmaz, Nihal and Özkuk, Kağan},
title = {Clinical efficacy of peloidotherapy on pain, sleep quality, and central sensitization-related symptoms in chronic low back pain: a comparative analysis},
journal = {International Journal of Biometeorology},
year = {2026},
doi = {10.1007/s00484-026-03225-1}
}
EUVIMED